Wednesday, 21 October 2009
There is still no effective therapy for malignant pleural mesothelioma
Despite many years of clinical research, there is still no effective therapy for malignant pleural mesothelioma (MPM). In general, MPM is a disease confined to the pleural cavity for a long time before metastasizing. Therefore, focus on local treatment seems rational. Both asbestos and erionite can cause a variety of benign and malignant chest diseases. Among the latter, pleural mesothelioma is the most serious. The estimated incidence of malignant pleural mesothelioma has been reported to be 43 per million inhabitants in the south-east of Turkey alone. In a retrospective study, Selcuk et al. showed a relatively better survival in patients with malignant pleural mesothelioma caused by exposure to asbestos.
Parenchymal nodules were followed according to lung cancer screening recommendations, morphology and location of pleural plaques was noted in detail. Screening prior asbestos workers detects advanced malignant pleural mesothelioma and early as well as late stage lung cancer. Shotgun pyrosequencing is now used to characterize RNA mutations and expression levels unique to malignant pleural mesotheliomas (MPMs) and not present in control tissues.
Parenchymal nodules were followed according to lung cancer screening recommendations, morphology and location of pleural plaques was noted in detail. Screening prior asbestos workers detects advanced malignant pleural mesothelioma and early as well as late stage lung cancer. Shotgun pyrosequencing is now used to characterize RNA mutations and expression levels unique to malignant pleural mesotheliomas (MPMs) and not present in control tissues.
Monday, 19 October 2009
Malignant pleural mesothelioma is an uncommon....
Malignant pleural mesothelioma is an uncommon, but increasingly recognized, malignant neoplasm of the pleura. Patients diagnosed with pleural mesothelioma have cancerous growths in the tissues surrounding their lungs. Pleural mesothelioma is the medical term for the lethal mesothelioma lung cancer caused by the inhalation of asbestos fibres. There is no benign form of this disease. Mesothelioma can attack several areas of the body, but two thirds of all mesothelioma diagnoses are pleural.
Malignant mesothelioma of the pleura is a cancer which arises from the mesothelial cells found within the pleural membranes that cover the lungs. Malignant mesothelioma develops from the mesothelial cells of the pleura. Malignant mesothelioma is relatively uncommon compared to other tumours. Australia has the highest incidence of mesothelioma in the world.
Malignant mesothelioma of the pleura is a cancer which arises from the mesothelial cells found within the pleural membranes that cover the lungs. Malignant mesothelioma develops from the mesothelial cells of the pleura. Malignant mesothelioma is relatively uncommon compared to other tumours. Australia has the highest incidence of mesothelioma in the world.
Saturday, 17 October 2009
No known cure for malignant mesothelioma?
While there is currently no known cure for malignant mesothelioma, treatments are available with the most common being surgery, chemotherapy and radiation therapy. The role of surgery in the management of malignant pleural mesothelioma cannot be precisely defined. A worker in a Spanish city of Lezo, who worked with asbestos forty years ago, dies of Malignant Pleural Mesothelioma raising concerns of how dangerous asbestos can be for health. Malignant pleural mesothelioma (MPM) is a deadly disease that occurs in 2000 to 3000 people each year in the United States.
Studies of pleural mesothelioma patients show that important prognostic factors include stage of cancer, age, and histology. Studies have shown the median survival of patients with malignant pleural disease is 16 months. Owing to worldwide use of asbestos during the past century, the global incidence of mesothelioma is still increasing.
Studies of pleural mesothelioma patients show that important prognostic factors include stage of cancer, age, and histology. Studies have shown the median survival of patients with malignant pleural disease is 16 months. Owing to worldwide use of asbestos during the past century, the global incidence of mesothelioma is still increasing.
Thursday, 15 October 2009
Pleural Mesothelioma is the most common type of mesothelioma
Pleural Mesothelioma is the most common type of mesothelioma, appearing in some 70% of diagnosed cases. There is no evidence that radiotherapy could help to cure or to prolong the survival of patients with malignant pleural mesothelioma. In 80% of the patients with malignant pleural mesothelioma there is a clear history of occupational or domestic exposure to asbestos. Pleural mesothelioma is a cancer that affects the lining of the lungs.
This type is most common and most dangerous for asbestos exposure related illnesses. Also, in the advanced stages of pleural mesothelioma, the cancer may spread to other nearby organs, including the heart, abdomen, and lymph nodes. Ultimately, a definitive diagnosis of malignant pleural mesothelioma is achieved by the use of sophisticated x-rays such as CT scans and MRI scans.
This type is most common and most dangerous for asbestos exposure related illnesses. Also, in the advanced stages of pleural mesothelioma, the cancer may spread to other nearby organs, including the heart, abdomen, and lymph nodes. Ultimately, a definitive diagnosis of malignant pleural mesothelioma is achieved by the use of sophisticated x-rays such as CT scans and MRI scans.
Tuesday, 13 October 2009
Information on pleural mesothelioma
Information on pleural mesothelioma, one form of the deadly mesothelioma cancer. Pleural mesothelioma is a disease that affects the lining of the lungs, or lung pleura. Sometimes doctors refer to this disease as mesothelioma of the pleura. The diagnosis and management of malignant pleural mesothelioma are major challenges that often frustrate both patient and clinician alike. Other mineral fibres such as erionite, a naturally occurring fibrous zeolite crystal, are associated with mesothelioma in volcanic tuffs of the Cappadocia region of central Anatolia.
Pleural Mesothelioma - Prognosis, Symptoms and Treatment Options
Pleural mesothelioma develops in the lining of the lungs. Following diagnosis, patients may wish to undergo treatment such as surgery to remove tumours. In February 2004, the United States Food and Drug Administration approved pemetrexed for treatment of malignant pleural mesothelioma. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma.
Pleural Mesothelioma - Prognosis, Symptoms and Treatment Options
Pleural mesothelioma develops in the lining of the lungs. Following diagnosis, patients may wish to undergo treatment such as surgery to remove tumours. In February 2004, the United States Food and Drug Administration approved pemetrexed for treatment of malignant pleural mesothelioma. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma.
Subscribe to:
Posts (Atom)
